Angiotech Pharmaceuticals, Inc, a specialty pharmaceutical company focused on the incorporation of pharmaceutical compounds into implantable medical devices and biomaterials, announced that it has licensed its ChondroGel^TM biomaterial to Histogenics Corporation for use with its NeoCart^TM cartilage implant in cartilage and orthopedic tissue regeneration applications.

The ChondroGel biomaterial is a self-polymerizing hydrogel specially modified with collagen, which, in preclinical studies, has been shown to contribute to the support of healthy tissue growth and cartilage regeneration while anchoring cartilage implants. Histogenics' NeoCart^TM implant is currently under Phase I clinical study.